Compounds > tienoxolol
Page last updated: 2024-12-06

tienoxolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Tienoxolol is a non-selective beta-blocker that was developed for the treatment of glaucoma. It is believed to decrease intraocular pressure by reducing the production of aqueous humor. It is available as an ophthalmic solution, which is administered topically to the eye. Tienoxolol is also being investigated for potential use in the treatment of other conditions such as migraine headaches and hypertension. The synthesis of tienoxolol involves several steps, including the preparation of a key intermediate, 2-hydroxymethyl-4-methyl-5-thiazolecarboxylic acid. This intermediate is then reacted with a substituted phenylethylamine to form tienoxolol. Tienoxolol is a potent beta-blocker with a long duration of action. It has been shown to be effective in reducing intraocular pressure in patients with glaucoma. However, it is important to note that tienoxolol can cause a number of side effects, including blurred vision, eye irritation, and dry eyes. In addition, tienoxolol can interact with other medications, so it is important to discuss your medical history with your doctor before starting treatment with this medication. Tienoxolol is a promising drug for the treatment of glaucoma and other conditions. However, further research is needed to better understand its effects and to develop safer and more effective treatments. '

tienoxolol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65678
CHEMBL ID8148
SCHEMBL ID635256
MeSH IDM0159651

Synonyms (16)

Synonym
tienoxolol
ethyl 2-[3-(tert-butylamino)-2-hydroxypropoxy]-5-(thiophene-2-carbonylamino)benzoate
L004000
CHEMBL8148
90055-97-3
44mr81yq9r ,
unii-44mr81yq9r
tienoxolol [inn]
tienoxololum
tienoxololum [latin]
(+-)-ethyl 2-(3-(tert-butylamino)-2-hydroxypropoxy)-5-(2-thiophenecarboxamido)benzoate
(+/-)-ethyl 2-(3-(tert-butylamino)-2-hydroxypropoxy)-5-(2-thiophenecarboxamido)benzoate
SCHEMBL635256
benzoic acid,2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-5-[(2-thienylcarbonyl)amino]-,ethyl ester
Q15633993
DTXSID50869043

Research Excerpts

Overview

Tienoxolol is a pharmacologically active molecule. It combines a diuretic and a β-adrenoreceptor antagonist into a single molecule.

ExcerptReferenceRelevance
"Tienoxolol is a pharmacologically active molecule designed with the functional groups ketothiophene, alkyl benzoate and arylpropanolamine so as to combine a diuretic and a β-adrenoreceptor antagonist into a single molecule. "( Degradation pathways study of the natriuretic and β-adrenoceptor antagonist tienoxolol using liquid chromatography-electrospray ionization multistage mass spectrometry.
Bernard, M; Céolin, R; Do, B; Dugay, A; Gana, I; Guechot, C; Henriet, T; Rietveld, IB; Safta, F; Teulon, JM; Yagoubi, N, 2014)		2.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID168628Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 32 mg/kg at 0-4 h; 9.02/11.671986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168627Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 32 mg/kg at 0-2h; 7.42/9.641986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168821Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 32 mg/kg; 0.259/0.6801986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID40709The compound was tested for beta-2 adrenergic receptor blocking activity in dogs1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID42026Compound was tested for beta-1 adrenergic receptor blocking activity in dogs after 5 hr1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168629Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 32 mg/kg at 0-6 h; 9.99/13.011986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID42035Compound was tested for beta-1 adrenergic receptor blocking activity in dogs1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168614Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 16 mg/kg; 6.42/91986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168826Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 64 mg/kg; 0.207/0.7661986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID42025Compound was tested for beta-1 adrenergic receptor blocking activity in dogs after 1 hr1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168810Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 16 mg/kg; 0.207/0.5541986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168819Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 32 mg/kg; 0.207/0.6261986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168632Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 64 mg/kg; 6.42/11.251986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID40700The compound was tested for beta-2 adrenergic receptor blocking activity in dogs after 5 hr1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168637Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 128 mg/kg;. 207/1.3641986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168461Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 128 mg/kg; 6.42/15.081986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID168622Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 32 mg/kg; 6.42/9.831986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
AID40699The compound was tested for beta-2 adrenergic receptor blocking activity in dogs after 1 hr1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
[p-[(Thienylcarbonyl)amino]phenoxy]propanolamines derivatives as diuretic and beta-adrenergic receptor blocking agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
theophylline
[no description available]		1.9810dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		1.9810chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		1.9610benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		1.9610naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
aldosterone
[no description available]		3.351111beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		1.9810adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
adenosine-5'-(n-ethylcarboxamide)
Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.		1.9810adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		1.9810prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
6-ketoprostaglandin f1 alpha
6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.		1.9810prostaglandins Falphahuman metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials